Companies to leverage proprietary IgM antibody technology platform to discover agonists against three oncology targets and three immunology/inflammation targets
The summit also saw the launch of two important reports- Multi-Regional Clinical Trials (MRCT) and Value of OTC in India
Approval is based on results of a multicenter, randomized, open-labeled and controlled IDE clinical study that demonstrated the superiority of Agili-C™ implant to the current surgical standard of care, debridement and microfracture in the knee joint
World-leading companies, as well as small innovative research groups, regularly partner with Medanex for their outstanding cardiovascular services and timely, efficacious study outcomes.
A novel second-generation approach to achieve a safe, durable, and stable transgene expression to overcome the challenges of factor VIII replacement therapies
Dupixent peak sales ambition raised to more than €13 billion
The amalgamation will integrate business operations and provide impetus to the existing portfolio of Alembic
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
Clinical improvements were consistent across patient subgroups including age, gender, ethnicity, and IL-36 gene mutation status
There are currently no approved systemic treatments for prurigo nodularis; regulatory filings for prurigo nodularis planned in the first half of 2022
Subscribe To Our Newsletter & Stay Updated
